This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Beyond LLMs: How Propense.ai & Tempus AI are Shaking up Legacy Industries
by Andrew Rocco
While large language models have been the primary focus of Wall Street, the real asymmetric returns for savvy growth investors will likely come from lesser-known AI segments disrupting legacy industries. Firms like Propense.ai, with its AI-powered B2B cross-selling platform, are gaining traction.
Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy?
by Urmimala Biswas
BFLY outpaces TEM with stronger upside, leaner valuation, and expanding global reach in AI-powered diagnostics.
Zacks Investment Ideas feature highlights: Palantir, Tempus AI and Comfort Systems USA
by Zacks Equity Research
Palantir, Tempus AI and Comfort Systems USA are part of the Zacks Investment Ideas article.
These 3 AI-Related Stocks Crushed Earnings
by Derek Lewis
We continue to wade through the 2025 Q1 cycle, which has been notably positive for these three companies with AI exposure. How long will the theme persist?
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?
by Urmimala Biswas
President Donald Trump's new executive order aiming to cut U.S. drug prices could benefit Tempus AI.
These AI Stocks Posted Robust Results: Time to Buy?
by Derek Lewis
Several AI-related stocks have posted robust results throughout the Q1 earnings cycle, a list that includes Palantir and Tempus AI. Given their results, it's impossible to deny the staying power of AI, which is still likely in its early innings.
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?
by Urmimala Biswas
TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
by Zacks Equity Research
Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog.
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
by Urmimala Biswas
TEM stock rises for three successive days. Should you expect more upside ahead, or is it time to dump Tempus AI?
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?
by Urmimala Biswas
Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment? Let's see.